Press Releases

  • Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

2025-04-21T08:16:12+02:00April 21, 2025|Investor Information, Press Releases, Psychedelic News|

Psyence BioMed announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”). The Staff's determination is based on the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.

Read More

Psyence Biomed Announces $2.0 Million Private Placement

2024-12-24T09:36:59+02:00December 23, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant in a private placement.

Read More
Go to Top